Nafamostat Mesylate

• CAT Number: A000613
• CAS Number: 82956-11-4
• Molecular Formula: C₁₉H₁₇N₅O₂.2CH₄O₃S
• Molecular Weight: 539.59
• Purity: ≥95%
• Synonyms: FUT-175
• Target: Apoptosis
• Solubility: >27mg/mL in DMSO
• Storage: 3 years -20C powder
• IUPAC Name: (6-carbamimidoylnaphthalen-2-yl) 4-(diaminomethylideneamino)benzoate;methanesulfonic acid
• InChI: InChI=1S/C19H17N5O2.2CH4O3S/c20-17(21)14-2-1-13-10-16(8-5-12(13)9-14)26-18(25)11-3-6-15(7-4-11)24-19(22)23;2*1-5(2,3)4/h1-10H,(H3,20,21)(H4,22,23,24);2*1H3,(H,2,3,4)
• InChIKey: SRXKIZXIRHMPFW-UHFFFAOYSA-N
• SMILES: CS(=O)(=O)O.CS(=O)(=O)O.C1=CC(=CC=C1C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(=N)N)N=C(N)N

Nafamostat mesylate（Cat No.:A000613）is a synthetic serine protease inhibitor with strong anticoagulant and anti-inflammatory properties, widely used in Japan for acute pancreatitis and as an anticoagulant during extracorporeal circulation. It acts by inhibiting proteases such as trypsin, thrombin, and plasmin, thereby reducing blood clot formation and inflammation. Nafamostat’s rapid onset and short half-life make it ideal for conditions requiring precise, controlled anticoagulation. Additionally, it has shown potential in inhibiting viral entry in emerging research, positioning it as a candidate for further exploration in antiviral therapies.